Evaluation of the Relationship between Pathology Results and Pain Scores in Patients Who Underwent Transrectal Ultrasound-Guided Prostate
IF 0.1
Q4 ONCOLOGY
D. Bolat, M. E. Aydın, B. Gunlusoy, T. Değirmenci, Y. K. Topcu, İbrahim Küçüktürkmen, Y. Ceylan, E. Şefik
{"title":"Evaluation of the Relationship between Pathology Results and Pain Scores in Patients Who Underwent Transrectal Ultrasound-Guided Prostate","authors":"D. Bolat, M. E. Aydın, B. Gunlusoy, T. Değirmenci, Y. K. Topcu, İbrahim Küçüktürkmen, Y. Ceylan, E. Şefik","doi":"10.4274/UOB.666","DOIUrl":null,"url":null,"abstract":"© Üroonkoloji Bülteni, Ga le nos Ya yı ne vi ta ra fın dan ba sıl mış tır. Bu makale “Creative Commons Alıntı-Gayriticari-Türetilemez 4.0 Uluslararası Lisansı (CC BY-NC 4.0)” ile lisanslanmıştır. Objectives: In this study, we assessed the relationship between pain scores and the pathology results of patients who underwent transrectal ultrasound-guided prostate biopsy (TRUS-PBx). Materials and Methods: A total of 198 patients who underwent prostate biopsy between October 2014 and April 2015 due to abnormal digital rectal examination findings and/or high prostatespecific antigen (PSA) levels (≥2.5 ng/dL) were included in this study. Before the biopsy procedure, all patients underwent finger-guided transperineal periprostatic block with 10 mL of 2% prilocaine. A 10-point linear visual analogue scale (VAS) was used to assess the pain arising from probe insertion (VAS-1) and prostate sampling (VAS-2). After receiving the pathology results, the patients were grouped according to the presence of prostate cancer: Group 1: patients without prostate cancer and Group 2: patients with prostate cancer. Results: The mean age of the patients was 64±7.3 (43-83) years, and the mean PSA value was 12.5±18.3 (0.6-142) ng/dL. Prostate cancer detection rate was 22.7%. The mean VAS-1 score in Group 1 and group 2 was 1.6±1.8 and 2.0±2.5, respectively (p=0.209). The mean VAS-2 score in Group 1 and Group 2 was 2.5±2.4 and 2.6±2.6, respectively (p=0,725). Conclusion: The pain felt during TRUS-PBx is not related with the presence of prostate cancer on biopsy pathology.","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":null,"pages":null},"PeriodicalIF":0.1000,"publicationDate":"2016-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Uroonkoloji Bulteni-Bulletin of Urooncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/UOB.666","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 3
Abstract
© Üroonkoloji Bülteni, Ga le nos Ya yı ne vi ta ra fın dan ba sıl mış tır. Bu makale “Creative Commons Alıntı-Gayriticari-Türetilemez 4.0 Uluslararası Lisansı (CC BY-NC 4.0)” ile lisanslanmıştır. Objectives: In this study, we assessed the relationship between pain scores and the pathology results of patients who underwent transrectal ultrasound-guided prostate biopsy (TRUS-PBx). Materials and Methods: A total of 198 patients who underwent prostate biopsy between October 2014 and April 2015 due to abnormal digital rectal examination findings and/or high prostatespecific antigen (PSA) levels (≥2.5 ng/dL) were included in this study. Before the biopsy procedure, all patients underwent finger-guided transperineal periprostatic block with 10 mL of 2% prilocaine. A 10-point linear visual analogue scale (VAS) was used to assess the pain arising from probe insertion (VAS-1) and prostate sampling (VAS-2). After receiving the pathology results, the patients were grouped according to the presence of prostate cancer: Group 1: patients without prostate cancer and Group 2: patients with prostate cancer. Results: The mean age of the patients was 64±7.3 (43-83) years, and the mean PSA value was 12.5±18.3 (0.6-142) ng/dL. Prostate cancer detection rate was 22.7%. The mean VAS-1 score in Group 1 and group 2 was 1.6±1.8 and 2.0±2.5, respectively (p=0.209). The mean VAS-2 score in Group 1 and Group 2 was 2.5±2.4 and 2.6±2.6, respectively (p=0,725). Conclusion: The pain felt during TRUS-PBx is not related with the presence of prostate cancer on biopsy pathology.
经直肠超声引导前列腺检查患者病理结果与疼痛评分关系的评价
©Üroonkoloji b lteni, Ga le nos Ya yylne vi ta ra fın dan ba sıl mış tır。但请参阅“知识共享Alıntı-Gayriticari-Türetilemez 4.0 uluslararasyi lisansyi (CC BY-NC 4.0)”网址lisanslanmıştır。目的:在本研究中,我们评估了经直肠超声引导前列腺活检(truss - pbx)患者疼痛评分与病理结果之间的关系。材料与方法:2014年10月至2015年4月期间因直肠指检异常和/或前列腺特异性抗原(PSA)水平高(≥2.5 ng/dL)而行前列腺活检的198例患者纳入本研究。在活检之前,所有患者都用10ml 2%的丙胺卡因进行手指引导的经会阴前列腺周围阻滞。采用10分线性视觉模拟量表(VAS)评估探针插入(VAS-1)和前列腺取样(VAS-2)引起的疼痛。收到病理结果后,将患者按有无前列腺癌进行分组:1组为无前列腺癌患者,2组为有前列腺癌患者。结果:患者平均年龄64±7.3(43 ~ 83)岁,平均PSA值12.5±18.3 (0.6 ~ 142)ng/dL。前列腺癌检出率为22.7%。1、2组VAS-1平均评分分别为1.6±1.8、2.0±2.5分(p=0.209)。1、2组VAS-2平均评分分别为2.5±2.4分、2.6±2.6分(p= 0.725)。结论:活检病理显示,前列腺癌与TRUS-PBx手术疼痛无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。